pT3-EF1aH c-Met Citations (4)

Originally described in: Distinct pathways of genomic progression to benign and malignant tumors of the liver.
Tward AD, Jones KD, Yant S, Cheung ST, Fan ST, Chen X, Kay MA, Wang R, Bishop JM Proc Natl Acad Sci U S A. 2007 Sep 11;104(37):14771-6. Epub 2007 Sep 4. PubMed Journal

---

Articles Citing pT3-EF1aH c-Met

Articles
In a Rat Model of Acute Liver Failure, Icaritin Improved the Therapeutic Effect of Mesenchymal Stem Cells by Activation of the Hepatocyte Growth Factor/c-Met Pathway. Wang L, Li S, Wang HY, Zeng J, Zhang ZZ, Lv DY, Kuang WH. Evid Based Complement Alternat Med. 2019 Nov 7;2019:4253846. doi: 10.1155/2019/4253846. eCollection 2019. PubMed
Tyrosine phosphorylation of the scaffold protein IQGAP1 in the MET pathway alters function. Hedman AC, McNulty DE, Li Z, Gorisse L, Annan RS, Sacks DB. J Biol Chem. 2020 Dec 25;295(52):18105-18121. doi: 10.1074/jbc.RA120.015891. Epub 2020 Oct 21. PubMed
SLC13A3 is a major effector downstream of activated beta-catenin in liver cancer pathogenesis. Zhao W, Wang X, Han L, Zhang C, Wang C, Kong D, Zhang M, Xu T, Li G, Hu G, Luo J, Yee SW, Yang J, Stahl A, Chen X, Zhang Y. Nat Commun. 2024 Aug 30;15(1):7522. doi: 10.1038/s41467-024-51860-2. PubMed
Development of a cyst-targeted therapy for polycystic kidney disease using an antagonistic dimeric IgA monoclonal antibody against cMET. Schimmel MF, Bourgeois BC, Spindt AK, Patel SA, Chin T, Cornick GE, Liu Y, Weimbs T. Cell Rep Med. 2025 Sep 16;6(9):102335. doi: 10.1016/j.xcrm.2025.102335. Epub 2025 Sep 5. PubMed

If you have published an article using this material, please email us at to have your article added to this page.